Mirum Pharmaceuticals (MIRM) Stock Looks Reasonable Broadly Yet Stretched On Sales

Mirum Pharmaceuticals stock has delivered very strong gains over the past five years, yet current valuation checks suggest investors are now paying up for that track record. The company scores well on broader value screens, even as market based multiples lean toward an overvalued reading.

• Over five years, Mirum Pharmaceuticals has returned about 4.6 times the original investment, which places recent pricing in the context of a very large prior move.
• Expectations around Mirum Pharmaceuticals pipeline in liver disease, including potential from its Volixibat program, can support higher valuations, while clinical and regulatory uncertainty remains a key risk if milestones are delayed or trial outcomes fall short.
• The stock carries a high overall value score, which suggests that across several checks Mirum Pharmaceuticals still looks cheaper than many peers even though simple market multiples indicate it screens as overvalued.

The issue now is whether Mirum Pharmaceuticals current share price leaves enough room for future returns after such a strong multi year run and an overvalued signal from market multiples.

Scan beyond Mirum Pharmaceuticals to compare its multi year run and high value score with a curated set of 47 high quality undervalued stocks that may not yet reflect their full potential.

Does Mirum Pharmaceuticals Look Pricey on Sales?

P/S is often a useful cross-check for a company like Mirum Pharmaceuticals where revenue can be more meaningful than current earnings. Right now Mirum Pharmaceuticals trades on a P/S of about 10.6x, which is below the Biotechs industry average of roughly 13.2x and also sits under the peer group average of about 14.3x.

The Fair Ratio model, which looks at factors such as growth profile, margins, size and risk, points to a P/S of around 9.6x for Mirum Pharmaceuticals. That is lower than the current 10.6x multiple and indicates the stock is pricing in a premium to what this framework suggests is reasonable. Recent attention on liver disease treatments, including Volixibat, may help explain why investors are willing to pay above this fair P/S level.

On this P/S check, Mirum Pharmaceuticals stock screens as overvalued relative to the Fair Ratio benchmark.

See what the numbers say about this price — find out in our valuation breakdown.

The Mirum Pharmaceuticals Narrative: What Would Justify Today's Price?

Narratives for Mirum Pharmaceuticals pick up from this valuation puzzle and explain what kind of future path for revenue, margins and earnings would need to occur for the stock to be worth materially more or materially less than today’s price on Simply Wall St’s Community page. Instead of relying on a single multiple or model output, each narrative sets out its own assumptions about fair value so you can compare those expectations with actual results over time.

One of the top community narratives on Mirum Pharmaceuticals: 27% undervalued

"Multiple late-stage pipeline catalysts, including three pivotal study readouts over the next 24 months, set the stage for further product label expansions..."

Read one of the top narratives on Mirum Pharmaceuticals

Do you think there's more to the story for Mirum Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Mirum Pharmaceuticals now trades on market multiples that flag the stock as overvalued, even though broader valuation checks still look supportive. That split largely comes down to how much credit you think current pricing gives to the liver disease pipeline and future revenue potential. If you believe upcoming clinical and regulatory milestones land close to plan, today’s premium may feel acceptable. If you are more cautious on execution or timelines, the key question is whether the current multiple already reflects most of the good news.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com